Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

University of North Carolina Lineberger Comprehensive Cancer Center

Chapel Hill, NC

UNC Lineberger Comprehensive Cancer Center is a cancer research and treatment center at the University of North Carolina at Chapel Hill. Serving patients at the N.C. Cancer Hospital, UNC Lineberger is the only public comprehensive cancer center in the state of North Carolina.

One of the leading cancer centers in the nation, UNC Lineberger Comprehensive Cancer Center is located in Chapel Hill, North Carolina. As one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, UNC Lineberger was rated as exceptional – the highest category – by the National Cancer Institute. The center brings together some of the most exceptional physicians and scientists in the country to investigate and improve the prevention, early detection and treatment of cancer.

With research that spans the spectrum from the laboratory to the bedside to the community, UNC Lineberger faculty work to understand the causes of cancer at the genetic and environmental levels, to conduct groundbreaking laboratory research, and to translate findings into pioneering and innovative clinical trials.

Website: UNC Lineberger Comprehensive Cancer Center

Contact:

919-966-3036

Trials at this location:

HCRN GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Status: Open to Accrual
Read More

HCRN GU17-294

Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade

Status: Closed to Accrual
Read More

HCRN GI15-225

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225

Status: Closed to Accrual
Read More

HCRN GI17-319

A single arm, multi-center Phase 2 trial of mFOLFOX6 + trastuzumab + avelumab in first-line, metastatic, HER2-amplified gastric and esophageal adenocarcinoma

Status: Closed to Accrual
Read More

HCRN GU14-182

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182

Status: Closed to Accrual
Read More

HCRN GU15-217

UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217

Status: Closed to Accrual
Read More

HCRN GU15-262

Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Status: Closed to Accrual
Read More